United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
REDWOOD CITY, Calif., May 01, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it will release its financial results for the first quarter of 2017 after the close of trading on Thursday, May 4, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 14503879. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.
A replay of the call will be available beginning May 4, 2017 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on May 5, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 14503879. The webcast will also be available on Avinger's website for one year following the completion of the call.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
